| 1. Successful term pregnancies after laparoscopic excision of poorly differentiated Sertoli-Leydig cell tumor of the ovary. |
Page:201—204 |
| 2. Unusual involvement of cervix and vulva in a case of chronic lymphocytic leukemia. |
Page:205—206 |
| 3. Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer. |
Page:86—90 |
| 4. Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. |
Page:91—97 |
| 5. Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer. |
Page:98—102 |
| 6. Changes in biologic markers of oxidative stress and plasma endotoxin levels in gynecologic cancer patients treated with pelvic radiotherapy: a pilot study. |
Page:103—109 |
| 7. Does ductal lavage assert its role as a noninvasive diagnostic modality to identify women at low risk of breast cancer development?. |
Page:110—114 |
| 8. Photodynamic therapy for breast cancer in a BALB/c mouse model. |
Page:115—119 |
| 9. Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. |
Page:120—124 |
| 10. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. |
Page:274—281 |
| 11. Early diagnosis of malignant-transformed ovarian mature cystic teratoma: fat-suppressed MRI findings. |
Page:125—128 |
| 12. Successful pregnancy following transfer of frozen-thawed embryos in a patient with pseudomyxoma peritonei who underwent peritonectomy and bilateral oophorectomy. |
Page:129—132 |
| 13. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. |
Page:257—264 |
| 14. HE4, CA-125, and cystic ovarian mass. |
Page:133—133 |
| 15. Telesurgery is promising but still need proof through prospective comparative studies. |
Page:134—135 |
| 16. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. |
Page:257—264 |
| 17. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?. |
Page:207—209 |
| 18. Screening of uterine cervical cancer in low-resource settings. |
Page:137—138 |
| 19. Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix. |
Page:153—158 |
| 20. Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. |
Page:175—181 |
| 21. Radiation sigmoiditis mimicking sigmoid colon cancer after radiation therapy for cervical cancer: the implications of three-dimensional image-based brachytherapy planning. |
Page:197—200 |
| 22. Indications for endoscopy according to the revised FIGO staging for cervical cancer after MRI and CT scanning. |
Page:80—85 |
| 23. Hereditary portion as an initial genetic approach in gynecologic cancer: synchronous tumor of ovary and endometrium. |
Page:72—73 |
| 24. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. |
Page:265—273 |
| 25. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. |
Page:274—281 |
| 26. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. |
Page:265—273 |
| 27. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. |
Page:251—256 |
| 28. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. |
Page:242—250 |
| 29. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. |
Page:251—256 |
| 30. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. |
Page:235—241 |
| 31. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. |
Page:242—250 |
| 32. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. |
Page:226—234 |
| 33. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. |
Page:235—241 |
| 34. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. |
Page:217—225 |
| 35. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. |
Page:226—234 |
| 36. TGCS's Annual Meeting, August 10-12, 2012. |
Page:215—216 |
| 37. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. |
Page:217—225 |
| 38. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). |
Page:213—214 |
| 39. TGCS's Annual Meeting, August 10-12, 2012. |
Page:215—216 |
| 40. Emerging concept of tailored lymphadenectomy in endometrial cancer. |
Page:210—212 |
| 41. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). |
Page:213—214 |
| 42. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?. |
Page:207—209 |
| 43. Emerging concept of tailored lymphadenectomy in endometrial cancer. |
Page:210—212 |
| 44. 10th International Conference of ACOS, June 13-15 2012. |
Page:139—140 |
| 45. Awareness of cervical cancer screening among nursing staff in a tertiary institution of rural India. |
Page:141—146 |
| 46. Cervical cancer prevention program in Jakarta, Indonesia: See and Treat model in developing country. |
Page:147—152 |
| 47. Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement. |
Page:159—167 |
| 48. Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer. |
Page:168—174 |
| 49. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. |
Page:182—189 |
| 50. The effects of selenium on tumor growth in epithelial ovarian carcinoma. |
Page:190—196 |
| 51. Book Review: The emperor of all maladies: a biography of cancer. |
Page:291—292 |
| 52. Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma. |
Page:288—290 |
| 53. New insights into cervical cancer screening. |
Page:282—287 |
| 54. Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease. |
Page:11—15 |
| 55. Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media. |
Page:5—10 |
| 56. 9th Korea-Japan Gynecologic Cancer Joint Meeting. |
Page:3—4 |
| 57. The Journal of Gynecologic Oncology and the Asian Society of Gynecologic Oncology: the history, the present and the future. |
Page:1—2 |
| 58. How to make the best strategy to manage thromboembolism in ovarian cancer?. |
Page:78—79 |
| 59. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. |
Page:75—77 |
| 60. Late presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential. |
Page:69—71 |
| 61. Complete biologic response to taxane based chemotherapy confirmed by 18FFDG PET/CT and surgery in a cancer of unknown primary site. |
Page:65—68 |
| 62. Major clinical research advances in gynecologic cancer in 2011. |
Page:53—64 |
| 63. Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer. |
Page:48—52 |
| 64. Characteristics of thyroid incidentalomas detected by pre-treatment 18FFDG PET or PET/CT in patients with cervical cancer. |
Page:43—47 |
| 65. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. |
Page:35—42 |
| 66. Preoperative 18FFDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. |
Page:28—34 |
| 67. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. |
Page:22—27 |
| 68. Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009. |
Page:16—21 |
